Montreal Cognitive Assessment, a screening tool for Mild Traumatic Brain Injury: Prospective study

Suresh Kumar MD, P Shah, A Jawahar, MS
P7.185- AAN, Washington DC April 2015

Neuro-Headache, TBI & Cognitive Research Center, Shreveport, Louisiana, USA

INTRODUCTION

Montreal Cognitive Assessment devised by Nasreddine et al in 2005 as a quick screening tool to detect cognitive impairment, validated for dementia, of any neuro-degenerative pathology. MoCA is proven to be effective in sensitivity and specificity for detecting cognitive impairment in dementia.

No published study has examined the clinical utility of MoCA test in neuro-cognitive assessment of patients with mild traumatic brain injury. According to a recently published data by the CDC, approximately 40% of mTBI patients have at least one unmet need with problem even after one year of injury. The top three unmet needs were: improving memory and problem solving, managing stress and emotional upsets, and improving vocational skills at pre-injury level.

All the above needs are related to the neuro-cognitive impairment.

Material and Methods

In the past 36 months, we assessed 117 patients of mild traumatic brain injury at our center. The patient-age ranged from 19 to 82 years (mean age 44 years). There was male gender predominance (M:F = 60:57). The mean period elapsed between the injury and presentation varied from 0.5–36 months. Post traumatic headaches were the most common associated symptom (n = 83) followed by vertigo in 45 patients.

MATERIAL AND METHODS

In the past 36 months, we assessed 117 patients of mild traumatic brain injury at our center. The patient-age ranged from 19 to 82 years (mean age 44 years). There was male gender predominance (M:F = 60:57). The mean period elapsed between the injury and presentation varied from 0.5–36 months. Post traumatic headaches were the most common associated symptom (n = 83) followed by vertigo in 45 patients.

Results

The comparison to the MoCA composite scores of 27 correspond to the WMS IV 50 percentile with sensitivity 87.9% and specificity 66.7%.

Sensitivity of delayed recall 87.9% compare to the WMS IV at 50 percentile with 66.7% specificity. Average period of the WMS IV test from the TBI in mTBI group was 20 months.

The scores between 21-24 were most frequently noticed (44%) moderate followed by 25-27 (39%) mild and ≤ 20 (17%) severe.

Two thirds (66.6%) of the mTBI patients population had MoCA scores between 21 and 27 points mild to moderate cognitive deficit.

Memory Module # Abnormal Percentage

| DELAYED RECALL | 96 | 82.1 |
| VISUO-SPATIAL / EXECUTIVE | 78 | 66.7 |
| ATTENTION | 76 | 64.9 |
| LANGUAGE | 67 | 57.3 |
| NAMING | 11 | 9.4 |
| ABSTRACTION | 6 | 5.1 |
| ORIENTATION | 10 | 8.5 |

Recommendations:

• Mandatory 2 week and 3 month follow up after mTBI with Trained physician in TBI.
• Routine screening of mTBI patients with MoCA.
• MoCA can be further simplified as a spot screening tool but may need further study.
• MoCA also can be an effective tool to stratify the treatment plan for MTBI patients and needs further studies.

We are studying MoCA to further validate with Std WASI IV and NAB battery neuropsychology test.

CONCLUSIONS

Cognitive impairment persists in majority (75%) of patients even a year after mTBI from the point prevalence in our study.

Results Cont.

Assessment of cognitive impairment should be a mandatory protocol while evaluating patients of mTBI. MoCA is a quick and reasonably sensitive (87.9%) and specific (66.7%) test for cognitive impairment following mTBI and is a good screening tool.

A majority of the patients (67%) with mTBI will demonstrate a composite MoCA score between 21 and 27.

The modules of VISUO-SPATIAL, DELAYED RECALL, ATTENTION and LANGUAGE are the most commonly impaired cognitive functions in patients with mTBI. Orientation assessment is not significant in mTBI.

Contact:

Suresh Kumar M.D.
Board Certified Neurology & UCNS Headaches Medicine
Director of TBI & Neuro-cognitive rehab Center
Director of Neurology & Headache Center Inc.
3555 Youree Drive
Shreveport, LA 71105
Phone: 318-865-1200 Ext 6, Fax: 318-865-1300
www.srbheadahes.com & www.rezaimemorycenter.com
neuroheadachecenter.com
rezaimemorycenter.com